This post is not the latest immunisation update and therefore may contain information or advice that is out of date. Please see our most recent update here.
Changes from 6 February 2023 to human papillomavirus vaccination (Gardasil®9) dose schedule under the National Immunisation Program:
Routine schedule for people aged 12 to 13 years will change to a single dose (previously a 2 dose schedule)
Catch-up eligibility will be extended to include people up to and including 25 years of age.
Young people (except those who are immunocompromised) who receive a single dose before 26 years of age are considered fully vaccinated and will not need further doses.
State and Territory health departments will be communicating the changes to parents of adolescents eligible for the HPV vaccine at school in 2023.
From 6 February 2023, the routine 2-dose HPV vaccine schedule provided to young people aged 12 to 13 years will become a single dose schedule. The National Immunisation Program (NIP) provides the schedule using the same vaccine.
Expanded eligibility for Lagevrio and Paxlovid
Following advice from the Pharmaceutical Benefits Advisory Committee, the PBS eligibility criteria for Lagevrio and Paxlovid were expanded on 1 January 2023, to ensure greater access for people who are vulnerable to severe disease.
As part of the listing change on 1 January 2023, access has expanded to include:
patients with any significantly immunocompromising condition where in the last 12 months, the patient has received anti-CD20 monoclonal antibody treatment; and
patients who have been previously hospitalised with COVID-19 disease if subsequently re-infected (patients aged at least 50 years or First Nation’s patients aged at least 30 years).
This recommendation was clarified on 1 February 2023 to include ‘all patients over the age of 18 years who have been previously hospitalised with COVID-19 disease, if subsequently re-infected.’ Please see the COVID-19 oral treatments factsheet for more information.
A reminder also about eligibility for COVID-19 oral treatments. If you have a patient who tests positive for COVID-19, they may be eligible for antiviral treatments if they are:
70 years of age or older, regardless of risk factors and with or without symptoms
50 years of age or older with 2 additional risk factors for developing severe disease or have had a past COVID 19 infection resulting in hospitalisation
First Nations person, 30 years of age or older and with 1 additional risk factor for developing severe disease
18 years of age or older and moderately to severely immunocompromised.
Updated COVID-19 vaccination MBS items
From 1 February 2023, the COVID-19 vaccination MBS items have been streamlined and simplified to reflect integration of these services into routine care. The MBS benefits for these items have been adjusted so that no vaccine suitability assessment service will receive a lower MBS benefit than under the previous arrangements.
The flag-fall payment for vaccine suitability assessment services has been increased to cover the cessation of the In-reach Practice Incentive Program payment. The flag-fall is paid once for each visit to a residential aged care facility, residential disability facility, or a patient’s home. General practices are encouraged to consider their capacity to assist with in-reach vaccinations for aged care residents or workers and residential disability patients and workers.
Please be aware, COVID-19 vaccine suitability assessments and associated services are required to be bulk-billed, with no provider able to charge an additional fee for the service or require another service which has an out-of-pocket cost.
Free Translating Service
The Australian Government has created a free service to assist in the translating of personal documents. This service allows holders of certain types of visas to get key personal documents (such as immunisation history statements and other important medical information) translated for free. To start an application please visit the Free Translating Service website.
Immunisation overdue reports – order report here
CESPHN is inviting general practice to sign up to receive a regular report extracted on your behalf from the Australian Immunisation Register (AIR) which is specific to your practice – order by filling out this form.
Immunisation Education
Lunch and Learn: Immunisation catch ups
About: Please join us for an interactive lunch and learn presentation on immunisation catch up schedules. How to work them out, skills and insight to know in preparing a catch up schedule.
Register: Free – Click link to register. Please note numbers are limited as this session will be interactive.
NSW Flu Vaccination Update 2023 – RACGP Webinar
About: Participants will receive an update on the 2023 NSW Influenza Vaccination Program to help ensure they are well positioned to support their patients for the coming influenza season.
Maroubra Medicare Urgent Care Clinic (UCC) is now open The Maroubra Medicare Urgent Care Clinic (UCC) is now open, seven days a week, from 8.00am to 8.00pm. It was officially launched by member for Kingsford Smith, the hon Matt Thistlethwaite MP (pictured at the launch with CESPHN CEO Nathalie Hansen…
Media Release: Central and Eastern Sydney PHN releases Healthy Ageing Strategy to empower older people In response to the increasing longevity and rapid growth of the older population the Central and Eastern Sydney Primary Health Network (CESPHN) is proud to release its new Healthy Ageing Strategy 2023-2028. This comprehensive strategy…
Immunisation Weekly Update: Are your vaccines ready for summer? In the summer season, storms are more likely to occur, which can lead to power outages. Refer to the Cold Chain Toolkit to ensure all vaccination storage requirements are in place should an outage occur. Disposal of Zostavax® Zostavax® vaccine will…
Immunisation Weekly Update: COVID-19 XBB.1.5 vaccine onboarding The Australian Government has accepted the latest advice from ATAGI on the use of the new COVID-19 XBB 1.5 vaccine as part of the National COVID-19 Vaccine Program. All sites currently participating in the COVID-19 Vaccination Program will be onboarded for the three…
Immunisation Weekly Update: Increase in COVID-19 infection cases ATAGI notes a recent increase in COVID-19 cases since November 2023 across Australia and encourages all eligible people who have not yet had their recommended 2023 COVID-19 vaccine dose/s to receive them as soon as possible. A first 2023 dose is recommended…
Immunisation Weekly Update: Vaccination coverage in RACF Australian Immunisation Register (AIR) data suggests that only 36% of people aged 70+ living in the central and eastern Sydney PHN region are immunised against Pneumococcal diseases. Immunisation providers are reminded to check AIR immunisation history statements of patients going into Residential Aged…
Immunisation Weekly Update: Introduction of Shingrix® to the NIP From 1 November 2023, the shingles vaccine Shingrix® will replace Zostavax® on the National Immunisation Program (NIP) schedule for the prevention of shingles and post-herpetic neuralgia. It will be available for eligible people most at risk of complications from shingles. A…
NSW urged to prepare for heat wave Severe heatwave conditions are forecast in NSW in the coming days. Please read the NSW Health media release about taking steps to prevent heat-related illness. For further information about staying safe in a heatwave, visit Beat the heat and stay well during hot…